Results 121 to 130 of about 2,580 (202)

NUT carcinoma of the nasal cavity that responded to a chemotherapy regimen for Ewing’s sarcoma family of tumors: a case report

BMC Cancer, 2018
Background Nuclear protein in testis (NUT) carcinoma (NC) is a rare epithelial malignancy characterized by rearrangement of the NUT gene on chromosome 15. If NC is not suspected, it is often diagnosed as other malignancies.
Kohei Arimizu, Gen Hirano, Chinatsu Makiyama, Mioko Matsuo, Takakazu Sasaguri, Akitaka Makiyama   +5 more
doaj   +1 more source

Pulmonary NUT carcinoma, an elusive and refractory entity, shows transient response to chemotherapeutics and PD-1 inhibitor: a case report and literature review

Frontiers in Immunology
Nuclear protein of the testis (NUT) carcinoma (NC) is a rare but highly aggressive disease, characterized by drug resistance and poor prognosis. This report describes the case of a 32-year-old male patient diagnosed to have pulmonary NC; the tumor ...
Guangjian Yang, Runze Liu, Linke Yang, Xue Yang, Xiaoyong Tang, Huiqing Mao   +5 more
doaj   +1 more source

Expert consensus and current landscape of NUT carcinoma: A comprehensive strategy from diagnosis to treatment [PDF]

Nuclear protein of the testis (NUT) carcinoma is a rare and highly aggressive malignancy characterized by the rearrangement of the NUT midline carcinoma family member 1 (NUTM1) gene.
Lopes, JM
core   +1 more source

Aspects on the management of salivary gland mucoepidermoid carcinoma in Finland [PDF]

, 2012
According to the Finnish Cancer Registry, salivary gland cancer (SGC) is rare, with approximately 50 to 60 new cases in Finland annually. For pediatric patients, the Finnish Cancer Registry reported 15 new cases between 1990 and 2009.
Aro, Katri
core  

Etoposide and cisplatin in combination with anlotinib for lung NUT carcinoma: a case report

Frontiers in Oncology
Lung NUT carcinoma is a rare malignant tumor, which is highly aggressive, poorly differentiated, and difficult to recognize at an early stage, and is associated with very rare reports and extremely poor prognosis, with some reports showing a mOS of only ...
Yuxing Sun, Jiangyu Bian, Linfeng Wang, Tong Zhang   +3 more
doaj   +1 more source

2025 ACVIM Forum Research Abstract Program

Journal of Veterinary Internal Medicine, Volume 39, Issue 6, November/December 2025.
wiley   +1 more source

Therapeutic approaches to sinonasal NUT carcinoma: a systematic review [PDF]

PurposeSinonasal nuclear protein in testis carcinoma (SNUTC) is a rare, aggressive malignancy caused by genetic rearrangements in the NUTM1 gene. The prognosis of SNUTC ranks among the most unfavorable within the naso-sinusal district, with an overall ...
Albera, A, Albera, R, Fadda, GL, Felisati, G, Fuccillo, E, Maccari, A, Nitro, L, Pecorari, G, Pipolo, C, Saibene, AM, Urbanelli, A   +10 more
core   +1 more source

Unveiling the enigmatic primary pulmonary NUT carcinoma with WHSC1L1::NUTM1-rearrangement : a case-based insight and contemporary literature review

Surgical and Experimental Pathology
NUT carcinoma (NC) is a rare, aggressive, and genetically defined epithelial malignancy characterized by rearrangements involving the NUTM1 gene, most commonly BRD4::NUTM1 fusions.
Pallavi Majumdar, Paramita Paul, Arvind Suresh   +2 more
doaj   +1 more source

NUT carcinoma in pediatric patients: characteristics, therapeutic regimens, and outcomes of 11 cases registered with the German Registry for Rare Pediatric Tumors (STEP) [PDF]

Background and aims Nuclear protein of the testis (NUT) carcinoma (NC) is a rare and highly aggressive tumor defined by the presence of a somatic NUTM1 rearrangement, occurring mainly in adolescents and young adults.
Abele, Michael, Brecht, Ines B., Classen, Carl F., Dirksen, Uta, Flaadt, Tim, Frühwald, Michael C., Kloker, Linus, Kratz, Christian, Lauer, Ulrich M., Redlich, Antje, Schneider, Dominik T., Seitz, Christian, Wild, Hannah   +12 more
core   +1 more source

Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma. [PDF]

Oncogene, 2020
Zhang X, Zegar T, Lucas A, Morrison-Smith C, Knox T, French CA, Knapp S, Müller S, Siveke JT.   +8 more
europepmc   +1 more source